article thumbnail

SparkRx: The first digital therapeutic for adolescents

pharmaphorum

SparkRx is designed to decrease depression in individuals aged 13 to 22 by providing a multi-week programme based on cognitive behavioural therapy (CBT) and behavioural activation protocols. “In In primary care, there are guidelines to screening for behavioural health concerns like depression annually. About the author .

article thumbnail

Partnering to advance digital therapeutics offerings

pharmaphorum

Gani started BehaVR in 2016 to create DTx for mental and behavioural health. He says after a meeting between him and a leader at Sumitomo in 2018 or 2019, it became apparent both companies believed in the power of VR in mental health care. They also understand how to do clinical trial design,” Gani states.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What we’re expecting in 2021, and beyond…

pharmaphorum

There is an opportunity to address this at scale with digital tools and techniques, and expand support into just about any therapeutic area through the holistic integration of mental and behavioural health solutions that improve patient care. Clinical trials get more and more digitalised. About Healthware Group.

article thumbnail

Applied Virtual Reality in Healthcare: A comprehensive book on medical XR

pharmaphorum

Immersive technology can also help improve assessments of the effectiveness of treatment, particularly regarding behavioural health where a patient’s results are often subjective. The book notes pharma can utilise VR for clinical trials as it allows for a better understanding of the research subject. About the author .

article thumbnail

Drug discovery predictions: Analysis and insight 

Drug Discovery World

Here, Thomas reflects specifically on Anita Cooper’s prediction relating to the importance of clinical trials. . Following the launch of Protas, DDW spoke with Protas Chief Executive, Professor Sir Martin Landray, who echoed Cooper’s emphasis on the importance of clinical trial design.